Enterprise Value

2.818B

Cash

2.108B

Avg Qtr Burn

-39.86M

Short % of Float

17.49%

Insider Ownership

1.86%

Institutional Own.

71.14%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

CTX110 (CD19) Details
CD19+ malignancies, Blood cancer, B-cell malignancies, Cancer

Phase 2

Data readout

VCTX211 Details
Type 1 diabetes

Phase 1/2

Data readout

Phase 1/2

Update

Phase 1/2

Update

VCTX210 Details
Type 1 diabetes

Phase 1

Data readout

CTX310 (ANGPTL3) Details
Atherosclerotic cardiovascular disease

Phase 1

Data readout

CTX320 Lp(a) Details
Atherosclerotic cardiovascular disease

Phase 1

Data readout

CTX131 (CD70) Details
Cancer, Solid tumor/s

Phase 1

Data readout

CTX112 (CD19) Details
B-cell malignancies, Cancer, CD19+ malignancies, Blood cancer

Phase 1

Data readout

CTX130 (CD70) Details
Blood cancer, Cancer, T-cell lymphoma

Phase 1

Update

CTX120 (BCMA) Details
Multiple myeloma, Blood cancer, Cancer

Failed

Discontinued